Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Asian Currencies Trade Flat as Dollar Retreats After Fed Decision 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
UK Vehicle Production Falls Sharply in 2025 Amid Cyberattack, Tariffs, and Industry Restructuring 
Gold Prices Pull Back After Record Highs as January Rally Remains Strong 
Gold Prices Hit Record High Above $5,500 as Iran Strike Fears Fuel Safe-Haven Demand 
The Maire - EuroChem Case: Three Lessons for Global Business 
Indonesian Stocks Plunge as MSCI Downgrade Risk Sparks Investor Exodus 
Oil Prices Surge Toward Biggest Monthly Gains in Years Amid Middle East Tensions 
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
Wall Street Slips as Tech Stocks Slide on AI Spending Fears and Earnings Concerns 
U.S. Dollar Slides for Second Week as Tariff Threats and Iran Tensions Shake Markets 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
Advantest Shares Hit Record High on Strong AI-Driven Earnings and Nvidia Demand 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Namyang Dairy Product recently lost two of its leaders - chairman Hong Won Sik and CEO Lee Kwang Bum this week. The two decided to leave over the controversies created by the company’s claim about the effectiveness of its Bulgaris yogurt in fighting COVID-19 symptoms.
The controversy that led to Namyang’s heads exit
Chairman Hong Won Sik stepped down on Tuesday, May 4, and he announced his departure through a press conference. CEO Lee Kwang Bum also left his job on Monday, and their exit came two days after Namyang Dairy’s offices were raided by the authorities as it investigates the COVID-19 false claims.
The two resigned three weeks after the company held a symposium and announced that its Bulgaris yogurt effectively lowers the chance of contracting COVID-19 by at least 77%. However, the South Korean Ministry of Food and Drug Safety called out Namyang for such doubtful claims and immediately launched an investigation.
The public reportedly flocked to grocery stores to buy Namyang’s Bulgaris yogurts, and the company experienced a surge in its shares. This is another reason why a probe has been launched.
New scandal besetting the dairy company
Now, while the yogurt controversy is not yet over, The Korea Times reported that Namyang is facing a new issue. This time it has something to do with a patent infringement violation.
The outlet reported that Namyang’s Inner Care yogurt drink comes with a supplement pill. This is placed in the cap so it can easily be taken when drinking the yogurt. However, the company’s rival, Korea Yakult, that sells MPRO3, which is a probiotics beverage, claimed that the yogurt and pill combination was imitated by Namyang from them.
MPRO3 also comes with a supplement, and Yakult Korea is claiming that they are the originator of this product that was first launched in 2019. On the other hand, Namyang’s Inner Care was only released in February.
With the identical special features between Inner Care and MPRO3, Natural Way, which has the patent rights over Yakult Korea’s design of placing the pill inside the bottle caps, filed a patent lawsuit against Namyang. It was revealed that the filing was done last month.
